Global Pruritus Drug Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Pruritus Drug Market Analysis

The pruritus drug market is witnessing significant growth, driven by the increasing prevalence of pruritic conditions such as allergic contact dermatitis, eczema, and chronic skin disorders. The global market is projected to expand due to rising healthcare expenditures and heightened awareness of treatment options. Recent developments in the field include the introduction of innovative therapeutics, such as biologics and targeted therapies, which offer improved efficacy and safety profiles. For instance, the FDA's approval of nemolizumab, a monoclonal antibody for the treatment of prurigo nodularis and moderate to severe atopic dermatitis, marks a significant advancement in pruritus management. In addition, ongoing research into novel compounds and combination therapies aims to enhance treatment outcomes for patients with difficult-to-treat pruritic conditions. Furthermore, the expansion of telemedicine and digital health solutions is improving access to dermatological care, facilitating timely diagnosis and treatment of pruritus, ultimately driving the market for expansion.

Pruritus Drug Market Size

The global pruritus drug market size was valued at USD 7.61 billion in 2023 and is projected to reach USD 11.32 billion by 2031, with a CAGR of 5.10% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Pruritus Drug Market Trends

“Increasing Use of Biologics”

The global pruritus drug market is experiencing significant growth, influenced by the increasing prevalence of chronic skin conditions and the rising awareness of treatment options. One notable trend is the shift towards biologics, which are increasingly used to manage pruritus associated with conditions like atopic dermatitis and psoriasis. For instance, drugs such as Dupilumab have shown promising results in alleviating itching and improving skin conditions. Furthermore, the expansion of telemedicine is enhancing patient access to dermatological consultations, facilitating timely diagnoses and treatment plans. This trend is crucial as it empowers patients and aligns with the growing demand for personalized healthcare solutions. With the integration of advanced therapies and patient-centric approaches, the pruritus drug market is poised for robust expansion, addressing unmet needs and improving the quality of life for millions suffering from itching-related ailments.

Report Scope and Pruritus Drug Market Segmentation         

Pruritus Drug Market Definition

Pruritus drugs are medications specifically designed to alleviate itching (pruritus) caused by various conditions, including allergic reactions, skin disorders, and underlying systemic diseases. These drugs work through different mechanisms to reduce the sensation of itch and provide relief. Common classes of drugs for pruritus include antihistamines, which block histamine receptors to prevent allergic responses; corticosteroids, which reduce inflammation and immune response; and topical agents, such as calamine or menthol, which provide cooling effects. By targeting the underlying causes or symptoms of pruritus, these medications aim to improve patient comfort and quality of life.

Pruritus Drug Market Dynamics

Drivers

• Growing Aging Population

The aging population is significantly influencing the pruritus drug market, as older adults are more prone to skin conditions that lead to itching and discomfort. According to the United Nations, by 2030, the number of individuals aged 60 and older is projected to reach 1.4 billion, representing a substantial increase from 1 billion in 2019. Such demographic shift is critical, as age-related skin changes, such as reduced skin barrier function and chronic conditions like xerosis (dry skin), make older adults particularly susceptible to pruritus. For instance, studies show that older adults who experiences pruritus, their quality of life get severely impacted and lead to further complications, including skin infections and sleep disturbances. Consequently, the demand for specialized treatments that address the unique needs of this age group is increasing, consequently driving the market growth.

• Increasing Prevalence of Chronic Skin Disorders

The increasing prevalence of chronic skin disorders, including atopic dermatitis, psoriasis, and eczema, serves as a crucial market driver for the pruritus drug market, significantly boosting the demand for effective management solutions. The World Health Organization (WHO) reports that skin disorders affect nearly 900 million people globally, representing approximately 30% of the global population at some point in their lives. Specifically, atopic dermatitis affects 20% of children and up to 10% of adults worldwide, particularly in urban areas. In parallel, psoriasis impacts around 125 million people globally, often leading to severe itching and discomfort. This growing burden of skin disorders highlights the urgent need for innovative treatments and management strategies. As a result, pharmaceutical companies are increasingly focusing on developing targeted therapies that not only alleviate pruritus but also enhance the overall quality of life for affected individuals, making chronic skin conditions a significant driver of growth in the pruritus drug market.

Opportunities

• Rising Advancements in Targeted Therapies

Advancements in targeted therapies have revolutionized the treatment landscape for chronic pruritus by enabling more precise interventions that address specific underlying causes of itching. For instance, the introduction of IL-31 receptor antagonists, such as nemolizumab, has shown promising results in clinical trials, with studies indicating a significant reduction in pruritus in patients with atopic dermatitis compared to placebo. Such advancements enhances treatment efficacy and safety and  aligns with the broader trend of personalized medicine, offering tailored approaches to individual patients based on their specific conditions and responses to treatment. As a result, broadening market opportunities.

• Increasing Frequency of Special Designations from Regulatory Authorities

The global pruritus drug market is poised for significant growth, bolstered by the increasing frequency of special designations from regulatory authorities. Initiatives such as the FDA's Orphan Drug Designation and Breakthrough Therapy Designation are accelerating the development of new therapies targeting pruritus. For instance, the FDA granted Breakthrough Therapy Designation to Dupilumab for the treatment of pruritus associated with atopic dermatitis, recognizing its potential to provide significant improvements over existing treatments. Such designation not only expedites the drug's development and review process but also encourages investment in research and development by pharmaceutical companies. As regulatory bodies continue to support the development of novel treatments, the pruritus drug market stands to benefit from enhanced patient access to effective therapies, creating further opportunities in the pruritus drug market.

Restraints/Challenges

• High Treatment Costs

High treatment costs represent a significant challenge for the global pruritus drug market, potentially limiting patient access to effective therapies. The rising prices of innovative treatments, particularly biologics, can create barriers for patients and healthcare systems. For instance, the annual cost of Dupilumab, a leading biologic for treating pruritus associated with atopic dermatitis, can exceed several thousand USD in the United States, making it unaffordable for many patients without adequate insurance coverage, thereby making high treatment costs a critical market challenge within the pruritus drug sector.

• Patent Expiration of Branded Drugs

The patent expiration of branded drugs poses a considerable challenge to the global pruritus drug market, as it leads to the introduction of generic versions that can significantly alter market dynamics. When patents expire, generic manufacturers can produce lower-cost alternatives, which often results in reduced revenue for original brand-name drug manufacturers. For instance, the patent for Dupilumab is set to expire in 2028, paving the way for generic competitors that could offer similar efficacy at a fraction of the cost. In addition, the introduction of generics may dilute brand loyalty and complicate patient access to established therapies, particularly if the generic versions do not match the original in terms of efficacy or safety. Therefore, the patent expirations and subsequent rise of generics present significant challenges for maintaining revenue growth and innovation within the pruritus drug market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Pruritus Drug Market Scope

The market is segmented on the basis of types, drugs, route of administration, end users, and distribution channels. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Chronic Kidney Disease associated Pruritus
• Chronic Liver Disease associated Pruritus
• Atopic Dermatitis Associated Pruritus
• Others

Drugs

• Corticosteroids
• Antihistamines
• Counterirritants
• Others

Route of Administration

• Injectable
• Topical
• Oral
• Others

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retailers
• Others

Pruritus Drug Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, types, drugs, route of administration, end users, and distribution channels as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the market primarily due to its robust healthcare infrastructure, which supports the adoption of advanced medical technologies. In addition, the region is witnessing an increasing prevalence of hematologic diseases, driving demand for effective treatment solutions. This combination of infrastructure and rising health concerns positions North America as a key player in the market.

The Asia-Pacific region is expected to achieve the highest growth rate and demonstrate the strongest compound annual growth rate (CAGR) during the forecast period. This growth can be attributed to increasing investments in healthcare infrastructure development, a rising incidence of allergic contact dermatitis and urticaria, and growing awareness of available treatment options. These factors collectively contribute to a favorable environment for the expansion of healthcare services and products in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Pruritus Drug Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Pruritus Drug Market Leaders Operating in the Market Are:

• AbbVie Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Amgen Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Cara Therapeutics (U.S.)
• Enteris BioPharma (U.S.)
• NeRRe Therapeutics (U.K.)
• Vyne Therapeutics Inc. (U.S.)
• XBiotech USA, Inc. (U.S.)
• Ipsen Pharma (France)
• Eledon Pharmaceuticals, Inc. (U.S.)
• Amorepacific (South Korea)
• RDD Pharma, Ltd. (Israel)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Sanofi (France)
• Sun Pharmaceutical Industries Ltd. (India)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Takeda Pharmaceutical Company Limited (Japan)

Latest Developments in Pruritus Drug Market

• In February 2024, Galderma announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application for nemolizumab. This application is intended for the treatment of prurigo nodularis, as well as for adolescents and adults with moderate to severe atopic dermatitis
• In September 2023, Cara Therapeutics, Inc., a biopharmaceutical company, announced that its licensing partner, Maruishi Pharmaceutical Co., Ltd., has obtained approval from Japan's Ministry of Health, Labour and Welfare for the manufacturing and marketing of KORSUVA IV Injection Syringe. This approval is specifically for treating pruritus in patients undergoing hemodialysis, representing a notable advancement in the management of this condition

SKU-46133